Q Bio, a Redwood City, CA-based provider of clinically-relevant assessment solutions of personal human health, came out of stealth mode and secured $40m in Series B funding.
The round, which brings total funding raised to date to $58m, was led by Andreessen Horowitz. Other investors include Khosla Ventures, Founders Fund, Beast Ventures, Thirty5 Venturers, Sea Lane Venturers and SciFi VC.
The company intends to use the funds to continue to improve its proprietary platform and technology.
Founded in 2015 by serial entrepreneur Jeff Kaditz, Dr. Michael Snyder and Dr. Garry Choy, Q Bio has spent the last few years in stealth mode, focused on advancing its imaging protocols and determining the most clinically-relevant set of biomarkers to include in its platform that can look for existential risks in an asymptomatic population. In 75 minutes or less, members are able to get a comprehensive picture of their health and receive a web-based dashboard that they can review from anywhere in the world with their chosen clinicians. The company opened to a limited membership in late 2019 and plans to open additional locations this year.
As part of this new round of funding, Vijay Pande, general partner, Andreessen Horowitz, along with Vinod Khosla from Khosla Ventures will formally join Kaditz on the company’s Board of Directors. Clarissa Shen, who joined in 2019 as Q Bio Chief Operating Officer, will also join as a Board Observer.
FinSMEs
20/02/2020